Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation

Agus Rizal Ardy Hariandy Hamid, Gerald W. Verhaegh, Frank P. Smit, Cindy Van Rijt-Van De Westerlo, Inna Armandari, Andre Brandt, Fred C.G.J. Sweep, John P.M. Sedelaar, Jack A. Schalken

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Purpose: Dihydrotestosterone is the main active androgen in the prostate and it has a role in prostate cancer progression. After androgen deprivation therapy androgen receptor signaling is still active in tumor cells. Persistent intratumor steroidogenesis and androgen receptor changes are responsible for this continued activity, which influences the efficacy of prostate cancer treatment. We hypothesized that combining a 5α-reductase inhibitor and an antiandrogen would block intratumor androgen synthesis and androgen receptor protein activity. Thus, it would act synergistically to reduce tumor cell proliferation. Materials and Methods: The expression level of 5α-reductase and androgen receptor in endocrine therapy naïve prostate cancer and castration resistant prostate cancer tissues, and cell line models was determined by microarray and quantitative polymerase chain reaction analysis. Intracellular androgen was measured with radioimmunoassay. Tumor cell proliferation was determined using coloric MTT assay. The synergistic effects of combination treatments on tumor cell proliferation were calculated using the Chou-Talalay equation. Results: In all prostate cancer cases 5α-reductase-1 and 3 were up-regulated. Androgen receptor was up-regulated in metastatic prostate cancer and castration resistant prostate cancer cases. The 5α-reductase inhibitor dutasteride effectively decreased dihydrotestosterone production in prostate cancer and castration resistant prostate cancer cell lines. Furthermore, dutasteride combined with the novel antiandrogen enzalutamide synergistically suppressed endocrine therapy naïve prostate cancer and castration resistant prostate cancer cell proliferation. Conclusions: In this study the combination of a 5α-reductase inhibitor and (novel) antiandrogens synergistically inhibited tumor cell proliferation. These findings support clinical studies of combinations of a 5α-reductase inhibitor and (novel) antiandrogens as first line treatment of prostate cancer and castration resistant prostate cancer.

Original languageEnglish
Pages (from-to)1023-1029
Number of pages7
JournalJournal of Urology
Volume193
Issue number3
DOIs
Publication statusPublished - 1 Mar 2015

Keywords

  • MDV 3100
  • antineoplastic combined chemotherapy protocols
  • dutasteride
  • prostatic neoplasms
  • prostatic neoplasms, castration-resistant

Fingerprint Dive into the research topics of 'Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation'. Together they form a unique fingerprint.

Cite this